Latest Medtech News

Rewardle Holdings has reinforced its strategic position by increasing its stake in CloudHolter following a $100 million capital raise, while progressing towards ASX relisting after resolving financial reporting delays.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

Rewardle Holdings reported a strong March quarter with positive operational cash flow of $1.36 million, driven by its strategic partnership with MedTech firm CloudHolter, while progressing towards ASX relisting.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Rewardle Holdings reports a strong December quarter with positive cash flow and a significant valuation uplift in its CloudHolter partnership, underpinning its multi-pronged growth strategy.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.